BridgeBio has significantly advanced the development of the novel treatment for cardiac amyloidosis, employing Attruby. Preliminary trial results reveals significant benefits for individuals diagnosed with the severe https://attr-cm094609.blogdomago.com/40574403/bridgebio-progresses-attr-cm-treatment-with-the-drug